Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Amortization of Deferred Charges: 2016-2025

Historic Amortization of Deferred Charges for Aytu Biopharma (AYTU) over the last 7 years, with Sep 2025 value amounting to $29,000.

  • Aytu Biopharma's Amortization of Deferred Charges rose 7.41% to $29,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $110,000, marking a year-over-year decrease of 76.89%. This contributed to the annual value of $108,000 for FY2025, which is 81.91% down from last year.
  • As of Q3 2025, Aytu Biopharma's Amortization of Deferred Charges stood at $29,000, which was up 11.54% from $26,000 recorded in Q2 2025.
  • Aytu Biopharma's Amortization of Deferred Charges' 5-year high stood at $170,000 during Q4 2022, with a 5-year trough of -$165,000 in Q4 2021.
  • In the last 3 years, Aytu Biopharma's Amortization of Deferred Charges had a median value of $98,000 in 2023 and averaged $88,909.
  • In the last 5 years, Aytu Biopharma's Amortization of Deferred Charges plummeted by 451.06% in 2021 and then skyrocketed by 688.24% in 2022.
  • MRQ analysis of 5 years shows Aytu Biopharma's Amortization of Deferred Charges stood at -$165,000 in 2021, then surged by 203.03% to $170,000 in 2022, then dropped by 9.41% to $154,000 in 2023, then plummeted by 81.82% to $28,000 in 2024, then increased by 3.57% to $29,000 in 2025.
  • Its Amortization of Deferred Charges was $29,000 in Q3 2025, compared to $26,000 in Q2 2025 and $27,000 in Q1 2025.